Website
N/ATelephone
64.800.423.823
Address
Level 1 129 Hurstmere Road, Takapuna Nielsen House Auckland 0622
Description
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. It operates through the following geographical segments: Australia, New Zealand, Asia, and Rest of the World. The Australia segment caters to the Australian market. The New Zealand segment focuses on the head office function, supplier relationships and procurement of stock, and regulatory, marketing, and finance activities of the group. The Asia segment relates in the sales activities in Brunei, Hong Kong, Malaysia, Philippines, Singapore, and Vietnam markets. The Rest of the World segment consists of out licensing of internet protocol developments to markets in which the firm does not have a presence and the export of products to export markets. The company was founded by Hartley Atkinson and Marree Atkinson on September 4, 1997 and is headquartered in Auckland, New Zealand.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 3.05 - 3.7
Trade Value (12mth)
AU$436.00
1 week
-7.58%
1 month
-4.69%
YTD
-10.29%
1 year
-13.84%
All time high
5.25
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
105m
HALO Sector
Healthcare
Next Company Report Date
20-May-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 May 23 |
Dividend/Distribution - AFP
×
Dividend/Distribution - AFP |
30 May 22 |
Annual Meeting and Closing Date for Director Nominations
×
Annual Meeting and Closing Date for Director Nominations |
30 June 23 |
Notice of Annual Meeting of Shareholders 2023
×
Notice of Annual Meeting of Shareholders 2023 |
29 August 23 |
AFT Orphan Pharmaceuticals judgment
×
AFT Orphan Pharmaceuticals judgment |
28 April 22 |
Capital Change Notice
×
Capital Change Notice |
28 April 22 |
Application for quotation of securities - AFP
×
Application for quotation of securities - AFP |
27 March 23 |
NEW LICENSING AND APPROVALS
×
NEW LICENSING AND APPROVALS |
27 July 22 |
AFP Completes Pascomer Clinical Study and Takes Back Rights
×
AFP Completes Pascomer Clinical Study and Takes Back Rights |
26 May 23 |
Annual Meeting and Closing Date for Director Nominations
×
Annual Meeting and Closing Date for Director Nominations |
26 May 22 |
Capital Notice
×
Capital Notice |
26 May 22 |
Application for quotation of securities - AFP
×
Application for quotation of securities - AFP |
24 November 22 |
221124 Interim results FY23H1 release
×
221124 Interim results FY23H1 release |
24 November 22 |
221124 Interim results FY23H1 App 2
×
221124 Interim results FY23H1 App 2 |
24 November 22 |
221124 Interim results FY23H1 interim report
×
221124 Interim results FY23H1 interim report |
24 November 22 |
221124 Interim results FY23H1 presentation
×
221124 Interim results FY23H1 presentation |
24 November 22 |
221124 Interim results FY23H1 App 2 amended
×
221124 Interim results FY23H1 App 2 amended |
24 May 21 |
FY2021 Annual Report
×
FY2021 Annual Report |
24 May 21 |
FY 2021 AFT Financial Presentation
×
FY 2021 AFT Financial Presentation |
24 January 23 |
AFT announces Maxigesic IV distribution agreement for nine
×
AFT announces Maxigesic IV distribution agreement for nine |
24 August 20 |
Arrangements for the Adjourned 2020 Annual Meeting
×
Arrangements for the Adjourned 2020 Annual Meeting |
24 August 20 |
Notice of Adjourned Annual Meeting of Shareholders 2020
×
Notice of Adjourned Annual Meeting of Shareholders 2020 |
23 November 23 |
FY2024 Interim
×
FY2024 Interim |
23 November 23 |
FY2024 Interim
×
FY2024 Interim |
23 November 23 |
FY2024 Interim
×
FY2024 Interim |
23 May 22 |
FY2022 results
×
FY2022 results |
23 May 22 |
FY2022 App2
×
FY2022 App2 |
23 May 22 |
FY2022 Annual Report
×
FY2022 Annual Report |
23 May 22 |
FY2022 presentation
×
FY2022 presentation |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.